AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02284763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EtCO2
Description: Initial data collection during BCP was performed following three conditions were satisfied: after start of surgery; at least 15 min after BCP (for stabilization of MAP); after ventilation frequency was adjusted to produce EtCO2 of 27-29 mmHg with tidal volume of 8 ml/kg. Data was collected every 3 min after decreasing ventilation frequency by 1-2 breaths/min to increase EtCO2 until 42-45 mmHg. Once the value of EtCO2 42-45 mmHg was reached, ventilator frequency was increased in the same way to decrease EtCO2 until 27-29 mmHg. Fraction of inspired oxygen of 50% was maintained and end-tidal desflurane concentration was adjusted to achieve bispectral index values of 40-55 during data collection.
Study NCT04112095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norgestrel 0.075 mg tablets
Description: All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 24 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet.
Study NCT01197170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg by mouth daily of a 28 day cycle.
Study NCT01197170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting dose 10 mg by vein on day 1 of a 21 day cycle.
Study NCT01197170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Starting dose 5 mg by mouth daily for a 28 day cycle.
Study NCT01197170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose 200 mg by mouth twice a day of a 28 day cycle.
Study NCT01197170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Starting dose 75 mg by mouth daily for a 28 day cycle.
Study NCT01534364 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: calorie restriction
Description: Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
Study NCT03866733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continous erector spinea block
Description: Ultrasound guided erector spinea block will be performed while the patient is in left lateral position ) the US probe will be placed in longitudinal parasagittal plane lateral to the T5 spinous process. An 18-gauge epidural needle will be inserted in-plane in a cranial-to-caudal direction until the tip is deep to erector spinae muscle. A 5 cm of epidural catheter will be threaded in cephalad direction. The same steps will be performed on the other side, after the negative aspiration for blood, bolus dose 15 ml of 0.25% bupivacaine will be injected in each of the catheters followed by a continuous infusion of 0.125% plain bupivacaine at the rate of 0.1 ml/kg/h.
Study NCT03866733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous narcotics
Description: intervention: injection of boluses of intra venous Narcotic drugs (fentanyl) in the dose of (1-2mcg/kg) during the surgery after induction of anesthesia then fentanyl infusion through the postoperative first 24 hours postoperative till extubation then intravenous pethidine till 48 hours after surgery.
Study NCT02472743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-built phototherapy lamp
Description: Described in the arm description
Study NCT01942031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: structured collegial feed back
Description: Collegial feed back to primary care physicians at randomized primary care centers
Study NCT03286933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: 75 minute weekly group yoga classes for 8 weeks. Home program online.
Study NCT04969380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
Study NCT03180424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L Carnitine
Description: L Carnitine liquid, single daily dose of 2g orally.
Study NCT03180424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L Carnitine
Description: L Carnitine liquid, single daily dose of 2g orally.
Study NCT03180424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: Modified Otago exercise programme, 2 times a week with a duration of 45 minutes, to be supervised by a previously qualified and trained instructor. Follow up of the established plan includes an adequate monitoring, evaluating the evolution and the possible adverse effects that may appear.
Study NCT03180424 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supervised exercise
Description: Modified Otago exercise programme, 2 times a week with a duration of 45 minutes, to be supervised by a previously qualified and trained instructor. Follow up of the established plan includes an adequate monitoring, evaluating the evolution and the possible adverse effects that may appear.
Study NCT03180424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Liquid substance, similar to the one containing L carnitine, in the same presentation
Study NCT03180424 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise at home
Description: A schedule of exercises will be given in the consultation, which the patient will perform at home, without supervision
Study NCT01201174 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: fermented papaya preparation (FPP)
Description: Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
Study NCT02073565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrbusNeich Combo stent™
Description: The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
Study NCT02073565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus Eluting Stent (EES)
Description: Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
Study NCT02716493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation program
Description: The intervention was an 8-week home-based telerehabilitation program (three sessions of about 75 minutes per week) using the eChez-Soi telerehabilitation platform.~Through a unique software interface, the eChez-Soi allows for the following three technological aspects: 1- continuous data acquisition and recording from commercial biometric sensors; 2- continuous transmission of the collected data via the Internet to the clinician's computer, allowing the clinician to visualize the biomechanical and physiological parameters in real time; and 3- a challenging gaming environment with interactive exercises performed on musical rhythms.~In total, 15 supervised sessions and 9 unsupervised sessions were planned for a total of 24 exercise sessions
Study NCT01195844 — intervention group
Intervention type: BIOLOGICAL
Intervention: Rotavirus Vaccine
Description: This is an observational study evaluating hospitalizations and the medical care for the treatment of diarrhea from rotavirus infection in children \< 5 years of age; however, any rotavirus vaccines used in the children presenting with rotavirus-attributed diarrhea were evaluated, as well the prevalent rotavirus serotypes in this sample for future vaccine development.
Study NCT01789671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based behavioral intervention
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
Study NCT01789671 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based behavioral intervention
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
Study NCT03567993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: Participants randomized to the comparison arm will receive twice-monthly abstinence assessments from the text messaging system, with no motivational feedback. Those in the comparison arm are neither offered nor encouraged to participate in the intervention.
Study NCT03567993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants randomized to the intervention arm will receive:~1. Motivational Messages~2. Abstinence and Motivation to Use Services Assessments~3. Encouragement to access the Quitline~4. Encouragement to use Nicotine Replacement Therapy (NRT)~5. Provision of NRT, if requested~Intervention subjects are encouraged to access the Quitline and use NRT. However, these are not mandatory components of the intervention and subjects can choose if they would like to engage with the Quitline or use NRT.
Study NCT05138484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: experimental group 10% mouthwash of M. sylvestris extract
Description: To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.
Study NCT02962323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Rosuvastatin Calcium Tablets 40 mg
Description: Oral, crossover
Study NCT02962323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA
Description: Oral, crossover
Study NCT03724240 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: 4 x 2 injection over 21 days the dosage is100 µg/ml
Study NCT03724240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: 4 x 2 injection over 21 days the dosage is100 µg/ml
Study NCT01752894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-guided PCI with EES or BES
Description: Angio-guided intervention
Study NCT01752894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI with EES or BES
Description: OCT-guided intervention
Study NCT01752894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with BES under angio-guide or OCT guide
Description: biolimus A9-eluting stent.
Study NCT01752894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with EES under angio-guide or OCT guide
Description: everolimus eluting stent.
Study NCT01752894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keep DAPT
Description: maintain DAPT for 12 months according to level of uncovered strut (>6%) at 3months OCT follow up after stent implantation.
Study NCT01752894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Discontinue DAPT
Description: discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.
Study NCT03424629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose UC-MSCs
Description: Participants will receive 6 times UC-MSCs infusions (each time 1×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
Study NCT03424629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose UC-MSCs
Description: Participants will receive 6 times UC-MSCs infusions (each time 3×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
Study NCT03424629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15).
Study NCT03945097 — intervention group
Intervention type: BEHAVIORAL
Intervention: preK
Description: Subjects enter and education program that either focuses on learning letters and their corresponding sounds or on language comprehension skills.
Study NCT00925288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
Study NCT00925288 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
Study NCT00088452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethosuximide
Description: Ethosuximide is a common treatment for childhood absence epilepsy.
Study NCT00088452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine is a common treatment for childhood absence epilepsy.
Study NCT00088452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic acid
Description: Valproic acid is a common treatment for childhood absence epilepsy.
Study NCT04549142 — intervention group
Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study NCT02596399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSTA4637S
Description: Participants will receive DSTA4637S intravenously on Day 1.
Study NCT02596399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
Study NCT02007759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalStim
Description: This group will receive active VitalStim treatment.
Study NCT02007759 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VitalStim
Description: This group will receive a sham VitalStim intervention.
Study NCT02476708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin 1800mg
Description: Curcumin, derived from turmeric root, is an over-the-counter supplement which is tolerated well.
Study NCT02476708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo capsule
Study NCT03138746 — intervention group
Intervention type: PROCEDURE
Intervention: HBO
Description: Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow oxygen for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes
Study NCT03138746 — intervention group
Intervention type: PROCEDURE
Intervention: Hyperbaric air
Description: Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow air for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes
Study NCT00800956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-esreboxetine
Description: Single oral dose of 6mg esreboxetine in solution containing approximately 100uCi \[14C\]-esreboxetine
Study NCT00664456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant therapy
Description: AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
Study NCT03035006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipotecan
Description: Lipotecan based concurrent chemoradiotherapy
Study NCT01382316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Alcoholics Anonymous Easier (MAAEZ)
Description: 6-week, 90-minute, manualized, 12-step facilitation intervention consisting of 6 weekly session. First session is introduction. Four following core sessions attended in any order: sponsorship, principles not personalities, spirituality, living Sober. Last session, return to intro session as graduate.
Study NCT01382316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Group format, six weekly education sessions about alcohol and drugs
Study NCT02961062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAF312
Study NCT02961062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAF312
Study NCT02961062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02961062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00807391 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TBCA, TBNA
Description: One arm, in random order first transbronchial catheter aspiration and second transbronchial needle aspiration or vice verse, both techniques routinely used in the diagnosis of peripheral pulmonary lesions; the cytological specimens of TBCA and TBNA are in random order examined by two independent cytologists, all cytological specimens are afterwards examined by a third, supervising cytologist.
Study NCT03013296 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GIP-A
Description: GIP-A
Study NCT03013296 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03013296 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GLP-1 receptor antagonist Exendin[9-39]
Description: Exendin\[9-39\]
Study NCT03013296 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GIP-A + Exendin[9-39]
Description: GIP-A + Exendin\[9-39\]
Study NCT03349905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fresh transfer
Description: Women randomized in the non experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)~* All of their embryo kept in prolonged culture~* A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)~* Supernumerary blastocysts cryopreserved
Study NCT03349905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deferred-frozen embryo transfer
Description: Women randomized in the experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)~* All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.~* A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation
Study NCT02604173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
Study NCT02604173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
Study NCT02604173 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo pill and sham inhaler
Study NCT04549376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.4% NI
Description: Povidone iodine (PVP-I) nasal irrigation at concentration of 0.4%
Study NCT04549376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.5% NI
Description: Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5%
Study NCT04549376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.6% NI
Description: Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6%
Study NCT04549376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.5% NS
Description: Povidone iodine (PVP-I) nasal spray at concentration of 0.5%
Study NCT04549376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.6% NS
Description: Povidone iodine (PVP-I) nasal spray at concentration of 0.6%
Study NCT04549376 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: DW-NI
Description: Nasal irrigation will be provided by Distilled water
Study NCT04549376 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: DW-NS
Description: Nasal spray will be provided by Distilled water
Study NCT01124292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue Piercing
Description: Subjects brush their teeth, and then swish and spit with chlorhexidine mouthwash for 30-60s. Subjects would be placed in a semirecumbent position in a procedure chair. After marking the piercing site using a sterilized surgical marking pen the protruded tongue would be pierced. Anesthesia may be used during the piercing at the discretion of the operator and the subject. A sterilized titanium or surgical grade stainless steel piercing tongue stud would be placed in an appropriate position on the tongue to minimize complications from the piercing but also facilitate good functionality of the TDS.